logo-loader
RNS
viewSynairgen PLC

Synairgen plc - Holding(s) in Company

RNS Number : 5177A
Synairgen plc
27 March 2017
 

 

 

Synairgen plc

('Synairgen' or the 'Company')

 

Holding in Company

Southampton, UK,: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that it received notice on 24 March 2017 that Leonard Licht, a private investor, now holds 3,700,000 ordinary shares of 1 pence each in the capital of the Company through Boal & Co (as Trustees of the Trinity Pension Scheme (ref L.S. Licht)).

This represents 4.05% of the total voting rights of the Company.

 

For further enquiries, please contact:

 

Synairgen plc 

Richard Marsden, Chief Executive Officer

John Ward, Finance Director

Tel: + 44 (0) 23 8051 2800

 

finnCap

Geoff Nash, James Thompson (Corporate Finance)

Stephen Norcross, Simon Johnson (Corporate Broking)

Tel: + 44 (0) 20 7220 0500

 

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott / Jessica Hodgson / Laura Thornton

[email protected]

Tel: +44 (0) 20 3709 5701

 

About Synairgen 

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Leveraging scientific and clinical trial facilities at the University of Southampton and Southampton General Hospital, the Company uses in vitro and ex vivo models to progress opportunities into clinical development. The BioBank of human samples is used in these models to increase confidence in the likelihood of successful drug development. Core to Synairgen's business strategy is the realisation of value via licensing transactions - validated in June 2014 by the SNG001 agreement formed with AstraZeneca. In August 2015 the Company entered into a collaboration with Pharmaxis to develop an oral LOXL2 inhibitor to reduce fibrosis in patients with idiopathic pulmonary fibrosis (IPF). Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com. 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLLLFEEVRISFID

Quick facts: Synairgen PLC

Price: 34.5

Market: AIM
Market Cap: £51.55 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Synairgen PLC pleased with further positive data from lead COPD drug

Richard Marsden, chief executive of Synairgen plc (LON:SYN), tells Proactive's Andrew Scott data from the ongoing phase II study of their SNG001 drug suggests it's having the desired effect in boosting the antiviral defences of chronic obstructive pulmonary disease (COPD)...

on 28/6/18